CJC-1295 & Ipamorelin

Half-Life: Why a Covalent Bond Changes Everything

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

Native GHRH clears in minutes, dominated by DPP-4. Modified GRF (1-29) extends that to roughly thirty minutes by blocking DPP-4 and other cleavage sites. The DAC form extends it to days by binding covalently to albumin, which removes renal filtration as a route.

Key facts

Native GHRH
Minutes (DPP-4 dominated)
Modified GRF (1-29)
~30 minutes
CJC-1295 with DAC
Days
DPP-4 countermeasure
D-Ala at position 2
Renal countermeasure
Covalent albumin binding
Albumin half-life
~19 days

Three clearance problems, solved in sequence

Native GHRH faces enzymatic cleavage and renal filtration. The substitutions address the first: D-alanine at position 2 makes the peptide a non-substrate for DPP-4, and three further substitutions cover other cleavage points. That alone takes it from minutes to about thirty minutes, a real gain, and still short, because the molecule remains small enough to be filtered.

Why size still matters after the substitutions

At 3367.9 Da, Modified GRF (1-29) passes the glomerulus freely. Blocking proteases does nothing about that. To extend duration further, something has to make the molecule effectively larger in circulation, which is exactly what the DAC linker achieves by attaching it to a 66 kDa protein.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £42.99

Covalent versus reversible, and why it matters here

Semaglutide's fatty acid binds albumin reversibly, maintaining an equilibrium between free and bound. DAC forms a covalent bond to albumin's cysteine-34. The peptide is not in equilibrium. It is attached, and its duration is governed by albumin turnover rather than by a dissociation constant. Albumin's half-life is around nineteen days, which is why the DAC form lasts days rather than hours.

The physiological question that creates

GHRH signalling is normally pulsatile, and a covalently albumin-bound analogue produces sustained receptor exposure instead. Whether continuous stimulation produces the same downstream result as pulses is a real question, and Ionescu and Frohman addressed it directly in 2006, reporting that pulsatile GH secretion persists during continuous stimulation, the pituitary imposing its own rhythm on a constant signal.

Why the non-DAC form is not simply inferior

A short half-life is a design choice, not a defect. If the research question concerns a brief physiological-like pulse, a compound clearing in thirty minutes models that better than one producing continuous exposure for days. Which is appropriate depends entirely on what is being studied.

Frequently asked questions

Why is the DAC form so much longer-acting?

It binds covalently to albumin, so its duration tracks albumin turnover (around nineteen days) rather than its own clearance.

Do the substitutions alone give a long half-life?

No. They block enzymatic cleavage but not renal filtration, which is why Modified GRF (1-29) still clears in about thirty minutes.

Does continuous stimulation change GH release?

Ionescu and Frohman reported that pulsatile GH secretion persists during continuous stimulation, with the pituitary imposing its own rhythm.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More CJC-1295 & Ipamorelin articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.